Longevity News

Just weeks after announcing it would "step up" its acquisitions this year, Medtronic said it will shell out up to $58...

Source: FierceBiotech - Medtech • Published: 20 Feb 2026, 11:32

Just weeks after announcing it would "step up" its acquisitions this year, Medtronic said it will shell out up to $58...

Medtronic will pay up to $585 million to acquire privately held CathWorks, an Israeli developer of coronary artery disease diagnostic and treatment devices, signaling an acceleration in the company's acquisition strategy.

Read Original Source

Continue exploring

Related longevity signals

Nature - MainWill the mRNA flu shot work better than a regular seasonal one? What the science saysAn analysis of Moderna's newly approved mRNA influenza vaccine and the evidence on its efficacy, safety, and reformulation advantages for seasonal flu control.Fight Aging!Anti-Aging Medicine, a Small Specialty, Will Spread in Some Form to the Whole of MedicineAn analysis of how longevity-focused clinical practice and prevention strategies could expand from a niche specialty into mainstream medicine over time.LinkedIn𝗙𝗲𝗯𝗿𝘂𝗮𝗿𝘆 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝗲𝗱 $𝟮𝟯.𝟮𝗕+ 𝗶𝗻 𝘁𝗼𝘁𝗮𝗹 𝗵𝗲𝗮𝗹𝘁𝗵 & 𝘄𝗲𝗹𝗹𝗻𝗲𝘀𝘀 𝗱𝗲𝗮𝗹 𝗮𝗰𝘁𝗶𝘃𝗶𝘁𝘆. 1️⃣ $772M+ in venture funding 2️⃣ $22.2B+ in acquisitions 3️⃣ $198M+ in IPO… | Nicholas A. Gnan | 13 commentsFebruary corporate recap: $772M+ in venture funding, $22.2B+ in acquisitions, and $198M+ in IPO value. Highlights include Talkiatry's $210M Series D, Lotus Health AI's $41M raise, Big Health's $23.7M, Temple's $54M valuation, AstraZeneca's $18.5B deal with CSPC Pharmaceutical Group, and Eli Lilly's up-to-$2.4B acquisition of Orna Therapeutics. Deals span AI primary care, digital therapeutics, women's precision health, PFAS-focused probiotics, athlete wearables, and consumer 'better-for-you' brands.Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.